Skip to main content

Table 2 Logistic regression of optimal SCR associated factors in type II PSOCs

From: The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial

Variable Univariate Multivariate
Exp (B) Sig Exp (B) Sig
Age 1.02 0.04 1.00 0.35
Ascites 2.43 0.00 1.25 0.10
Optimal initial CRS 5.67 0.00 4.10 0.02
PFI 3.12 0.01 2.68 0.01
Recurrent status 1.96 0.00 1.84 0.02
SNAC 1.80 0.00 1.63 0.04
Stage 4.45 0.04 2.46 0.61
CA-125 level at relapse 1.00 0.00 1.01 0.45
  1. SCR secondary cytoreduction, CRS cytoreduction surgery, PSOCs Platinum-sensitive recurrent ovarian cancer, PFI Platinum free interval, NAC Neo-adjuvant chemotherapy, SNAC Secondary Neo-adjuvant chemotherapy
  2. Recurrent status including symptom or biomarker indicated relapse